A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Chronic heart failure; Left ventricular dysfunction
  • Focus Pharmacokinetics
  • Acronyms COSMIC-HF
  • Sponsors Amgen
  • Most Recent Events

    • 18 Sep 2017 Results published in the Cytokinetics Media Release
    • 18 Sep 2017 According to a Cytokinetics media release, additional results from this trial were presented in a Rapid Fire Abstracts Presentation at the 21st Annual Heart Failure Society of America Scientific Meeting 2017.
    • 11 Sep 2017 According to a Cytokinetics media release, additional results from this trial will be presented in a Rapid Fire Abstracts Presentation at the 21st Annual Heart Failure Society of America Scientific Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top